Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD TrialFrançois‐Clément Bidard, Aditya Bardia|Journal of Clinical Oncology|2022Cited by 676
Circulating Tumor Cells in Breast Cancer Patients Treated by Neoadjuvant Chemotherapy: A Meta-analysisFrançois‐Clément Bidard, Paul Cottu, Daisuke Takata et al.|JNCI Journal of the National Cancer Institute|2018Cited by 282
The clinical use of circulating tumor cells (CTCs) enumeration for staging of metastatic breast cancer (MBC): International expert consensus paperMassimo Cristofanilli, Klaus Pantel, Jean‐Yves Pierga et al.|Critical Reviews in Oncology/Hematology|2018Cited by 268
First-Line Camizestrant for Emerging <i>ESR1</i> -Mutated Advanced Breast CancerFrançois‐Clément Bidard, Nicholas C. Turner, Erica L. Mayer et al.|New England Journal of Medicine|2025Cited by 106
Design of SERENA-6, a phase III switching trial of camizestrant in <i>ESR1</i> -mutant breast cancer during first-line treatmentNicholas C. Turner, François‐Clément Bidard, Cynthia Huang Bartlett et al.|Future Oncology|2023Cited by 78